Novartis collaborating with Intel to help accelerate early-stage drug discovery using deep neural networks

June 05, 2018 | Case Study

Novartis is one of the world's largest pharmaceutical companies, with more than $50 billion in revenues, and as a firm has had a recent leadership transition, with new CEO Vas Narasimhan recently taking the helm. The new CEO has emphasized digital transformation and artificial intelligence, including a push to look for partnerships and acquisitions around drug discovery and development. Indeed, during the past few years the company has made some initial forays in this direction, including working with IBM's Watson arm around advanced breast cancer treatment and tapping McKinsey's QuantumBlack unit for work on clinical trial analysis. In parallel to these external collaborations, however, Novartis is also looking at how it can tap external vendors to improve the internal efficiency of its R&D staff and the experiments that they run around drug discovery.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978